hERG potassium channels and the structural basis of drug-induced arrhythmias

Chemical Research in Toxicology

Volumn 21, Issue 5, 2008, Pages 1005-1010

  Mitcheson, John S ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; CLOFILIUM; CYTOCHROME P450; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; VOLTAGE GATED CHANNEL FORMING PROTEIN; VOLTAGE GATED POTASSIUM CHANNEL; CARDIOTOXIN; DRUG;

AMINO ACID SEQUENCE; BINDING AFFINITY; CARDIOTOXICITY; CHANNEL GATING; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG METABOLISM; DRUG SAFETY; HEART ARRHYTHMIA; HEART CONTRACTION; HIGH THROUGHPUT SCREENING; HUMAN; LIVER METABOLISM; LONG QT SYNDROME; MEMBRANE STRUCTURE; PROTEIN FUNCTION; QT INTERVAL; QT PROLONGATION; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; SUDDEN DEATH; BINDING SITE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; PROTEIN CONFORMATION;

ARRHYTHMIAS, CARDIAC; BINDING SITES; CARDIOTOXINS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN CONFORMATION;

EID: 47549086709     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx800035b     Document Type: Review

References (65)

1. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., and Keating, M. T. (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795-803.
2. Roden, D. M., Lazzara, R., Rosen, M., Schwartz, P. J., Towbin, J., and Vincent, G. M. (1996) Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 94, 1996-2012.
3. Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., and De Ponti, F. (2005) QT prolongation through hERG K(+) channel blockade: Current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. 25, 133-166.
4. Eckhardt, L. L., Rajamani, S., and January, C. T. (2005) Protein trafficking abnormalities: A new mechanism in drug-induced long QT syndrome. Br. J. Pharmacol. 145, 3-4.
5. Kuryshev, Y. A., Ficker, E., Wang, L., Hawryluk, P., Dennis, A. T., Wible, B. A., Brown, A. M., Kang, J., Chen, X. L., Sawamura, K., Reynolds, W., and Rampe, D. (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 312, 316-323.
6. Wible, B. A., Hawryluk, P., Ficker, E., Kuryshev, Y. A., Kirsch, G., and Brown, A. M. (2005) HERG-Lite: A novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods 52, 136-145.
7. Dumaine, R., Roy, M. L., and Brown, A. M. (1998) Blockade of HERG and Kv1.5 by ketoconazole. J. Pharmacol. Exp. Ther. 286, 727-735.
8. Viskin, S. (1999) Long QT syndromes and torsade de pointes. Lancet 354, 1625-1633.
9. Doyle, D. A., Morais Cabral, J., Pfuetzner, R. A., Kuo, A., Gulbis, J. M., Cohen, S. L., Chait, B. T., and MacKinnon, R. (1998) The structure of the potassium channel: Molecular basis of K+ conduction and selectivity. Science 280, 69-77.
10. Jiang, Y. X., Lee, A., Chen, J. Y., Cadene, M., Chait, B. T., and MacKinnon, R. (2002) The open pore conformation of potassium channels. Nature 417, 523-526.
11. Jiang, Y., Lee, A., Chen, J., Ruta, V., Cadene, M., Chait, B. T., and MacKinnon, R. (2003) X-ray structure of a voltage-dependent K+ channel. Nature 423, 33-41.
12. Long, S. B., Campbell, E. B., and Mackinnon, R. (2005) Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 309, 897-903.
13. Long, S. B., Campbell, E. B., and Mackinnon, R. (2005) Voltage sensor of Kv1.2: Structural basis of electromechanical coupling. Science 309, 903-908.
14. Swartz, K. J. (2004) Towards a structural view of gating in potassium channels. Nat. Rev. Neurosci. 5, 905-916.
15. Chanda, B., and Bezanilla, F. (2008) A common pathway for charge transport through voltage-sensing domains. Neuron 57, 345-351.
16. Yifrach, O., and MacKinnon, R. (2002) Energetics of pore opening in a voltage-gated K(+) channel. Cell 111, 231-239.
17. Ding, S., Ingleby, L., Ahern, C. A., and Horn, R. (2005) Investigating the putative glycine hinge in Shaker potassium channel. J. Gen. Physiol. 126, 213-226.
18. Magidovich, E., and Yifrach, O. (2004) Conserved gating hinge in ligand- and voltage-dependent K+ channels. Biochemistry 43, 13242-13247.
19. Hardman, R. M., Stansfeld, P. J., Dalibalta, S., Sutcliffe, M. J., and Mitcheson, J. S. (2007) Activation gating of hERG potassium channels: S6 glycines are not required as gating hinges. J. Biol. Chem. 282, 31972-31981.
20. Rosenhouse-Dantsker, A., and Logothetis, D. E. (2006) New roles for a key glycine and its neighboring residue in potassium channel gating. Biophys. J. 91, 2860-2873.
21. Mitcheson, J. S., and Sanguinetti, M. C. (1999) Biophysical properties and molecular basis of cardiac rapid and slow delayed rectifier potassium channels. Cell. Physiol. Biochem. 9, 201-216.
22. Mitcheson, J., Perry, M., Stansfeld, P., Sanguinetti, M. C., Witchel, H., and Hancox, J. (2005) Structural determinants for high-affinity block of hERG potassium channels. Novartis Found Symp. 266, 136-150; discussion, 150-138.
23. Kamiya, K., Niwa, R., Mitcheson, J. S., and Sanguinetti, M. C. (2006) Molecular determinants of HERG channel block. Mol. Pharmacol. 69, 1709-1716.
24. Mitcheson, J. S., Chen, J., and Sanguinetti, M. C. (2000) Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol. 115, 229-240.
25. Milnes, J. T., Witchel, H. J., Leaney, J. L., Leishman, D. J., and Hancox, J. C. (2006) hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656. Biochem. Biophys. Res. Commun. 351, 273-280.
26. Stork, D., Timin, E. N., Berjukow, S., Huber, C., Hohaus, A., Auer, M., and Hering, S. (2007) State dependent dissociation of HERG channel inhibitors. Br. J. Pharmacol. 151, 1368-1376.
27. Witchel, H. J., Dempsey, C. E., Sessions, R. B., Perry, M., Milnes, J. T, Hancox, J. C., and Mitcheson, J. S. (2004) The low potency, voltage-dependent HERG blocker propafenone - Molecular determinants and drug trapping. Mol. Pharmacol. 66, 1201-1212.
28. Yellen, G. (1998) The moving parts of voltage-gated ion channels. Q. Rev. Biophys. 31, 239-295.
29. Webster, S. M., Del Camino, D., Dekker, J. P., and Yellen, G. (2004) Intracellular gate opening in Shaker K+ channels defined by high-affinity metal bridges. Nature 428, 864-868.
30. Labro, A. J., Raes, A. L., Bellens, I., Ottschytsch, N., and Snyders, D. J. (2003) Gating of shaker-type channels requires the flexibility of S6 caused by prolines. J. Biol. Chem. 278, 50724-50731.
31. Mitcheson, J. S., Chen, J., Lin, M., Culberson, C., and Sanguinetti, M. C. (2000) A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A. 97, 12329-12333.
32. Kamiya, K., Mitcheson, J. S., Yasui, K., Kodama, I., and Sanguinetti, M. C. (2001) Open channel block of HERG K(+) channels by vesnarinone. Mol. Pharmacol. 60, 244-253.
33. Perry, M., de Groot, M. J., Helliwell, R., Leishman, D., Tristani-Firouzi, M., Sanguinetti, M. C., and Mitcheson, J. (2004) Structural determinants of HERG channel block by clofilium and ibutilide. Mol. Pharmacol. 66, 240-249.
34. Perry, M., Stansfeld, P. J., Leaney, J., Wood, C., de Groot, M. J., Leishman, D., Sutcliffe, M. J., and Mitcheson, J. S. (2006) Drug binding interactions in the inner cavity of HERG channels: Molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol. Pharmacol. 69, 509-519.
35. Ridley, J. M., Milnes, J. T., Duncan, R. S., McPate, M. J., James, A. F., Witchel, H. J., and Hancox, J. C. (2006) Inhibition of the HERG K+ channel by the antifungal drug ketoconazole depends on channel gating and involves the S6 residue F656. FEBS Lett. 580, 1999-2005.
36. Sanchez-Chapula, J. A., Navarro-Polanco, R. A., Culberson, C., Chen, J., and Sanguinetti, M. C. (2002) Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J. Biol. Chem. 277, 23587-23595.
37. Sanchez-Chapula, J. A., Ferrer, T., Navarro-Polanco, R. A., and Sanguinetti, M. C. (2003) Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol. Pharmacol. 63, 1051-1058.
38. Fernandez, D., Ghanta, A., Kauffman, G. W., and Sanguinetti, M. C. (2004) Physicochemical features of the HERG channel drug binding site. J. Biol. Chem. 279, 10120-10127.
39. Ridley, J. M., Milnes, J. T., Witchel, H. J., and Hancox, J. C. (2004) High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: Resistance to mutations of the S6 residues Y652 and F656. Biochem. Biophys. Res. Commun. 325, 883-891.
40. Milnes, J. T., Crociani, O., Arcangeli, A., Hancox, J. C., and Witchel, H. J. (2003) Blockade of HERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol. 139, 887-898.
41. Dalibalta, S., Leaney, J., de Groot, M. J., Stansfeld, P., and Mitcheson, J. (2008) In Antitargets. Prediction and Prevention of Drug Side Effects (Vaz, R. J., and Klabunde, T., Eds.) pp 89-108, Wiley-VCH, Weinheim.
42. Lees-Miller, J. P., Duan, Y., Teng, G. Q., and Duff, H. J. (2000) Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: Involvement of S6 sites. Mol. Pharmacol. 57, 367-374.
43. Ficker, E., Jarolimek, W., Kiehn, J., Baumann, A., and Brown, A. M. (1998) Molecular determinants of dofetilide block of HERG K+ channels. Circ. Res. 82, 386-395.
44. Stansfeld, P. J., Gedeck, P., Gosling, M., Cox, B., Mitcheson, J. S., and Sutcliffe, M. J. (2007) Drug block of the hERG potassium channel: Insight from modeling. Proteins 68, 568-580.
45. Herzberg, I. M., Trudeau, M. C., and Robertson, G. A. (1998) Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels. J. Physiol. 511, 3-14.
46. Gessner, G., and Heinemann, S. H. (2003) Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br. J. Pharmacol. 138, 161-171.
47. Gessner, G., Zacharias, M., Bechstedt, S., Schonherr, R., and Heinemann, S. H. (2004) Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents. Mol. Pharmacol. 65, 1120-1129.
48. Chen, J., Seebohm, G., and Sanguinetti, M. C. (2002) Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc. Natl. Acad. Sci. U.S.A. 99, 12461-12466.
49. Schonherr, R., and Heinemann, S. H. (1996) Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. J. Physiol. (London) 493, 635-642.
50. Smith, P. L., Baukrowitz, T., and Yellen, G. (1996) The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379, 833-836.
51. Spector, P. S., Curran, M. E., Zou, A., Keating, M. T., and Sanguinetti, M. C. (1996) Fast inactivation causes rectification of the IKr channel. J. Gen. Physiol. 107, 611-619.
52. McPate, M. J., Duncan, R. S., Milnes, J. T., Witchel, H. J., and Hancox, J. C. (2005) The N588K-HERG K+ channel mutation in the 'short QT syndrome': Mechanism of gain-in-function determined at 37 degrees C. Biochem. Biophys. Res. Commun. 334, 441-449.
53. Cordeiro, J. M., Brugada, R., Wu, Y. S., Hong, K., and Dumaine, R. (2005) Modulation of I(Kr) inactivation by mutation N588K in KCNH2: A link to arrhythmogenesis in short QT syndrome. Cardiovasc. Res. 67, 498-509.
54. Numaguchi, H., Mullins, F. M., Johnson, J. P., Jr., Johns, D. C., Po, S. S., Yang, I. C., Tomaselli, G. F., and Balser, J. R. (2000) Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ. Res. 87, 1012-1018.
55. Ficker, E., Jarolimek, W., and Brown, A. M. (2001) Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K+ channels. Mol. Pharmacol. 60, 1343-1348.
56. Cordero-Morales, J. F., Cuello, L. G., and Perozo, E. (2006) Voltage-dependent gating at the KcsA selectivity filter. Nat. Struct. Mol. Biol. 13, 319-322.
57. Cordero-Morales, J. F., Cuello, L. G., Zhao, Y., Jogini, V., Cortes, D. M., Roux, B., and Perozo, E. (2006) Molecular determinants of gating at the potassium-channel selectivity filter. Nat. Struct. Mol. Biol. 13, 311-318.
58. Cordero-Morales, J. F., Jogini, V., Lewis, A., Vasquez, V., Cortes, D. M., Roux, B., and Perozo, E. (2007) Molecular driving forces determining potassium channel slow inactivation. Nat. Struct. Mol. Biol. 14, 1062-1069.
59. Panyi, G., and Deutsch, C. (2007) Probing the cavity of the slow inactivated conformation of shaker potassium channels. J. Gen. Physiol. 129, 403-418.
60. Hille, B. (2001) Classical mechanisms of block. Ion Channels of Excitable Membranes, pp 503-536, Sinauer Associates Inc., Sunderland, MA.
61. De Ponti, F., Poluzzi, E., Montanaro, N., and Ferguson, J. (2000) QTc and psychotropic drugs. Lancet 356, 75-76.
62. Stansfeld, P. J., Sutcliffe, M. J., and Mitcheson, J. S. (2006) Molecular mechanisms for drug interactions with hERG that cause long QT syndrome. Exp. Opin. Drug Metab. Toxicol. 2, 81-94.
63. Sanguinetti, M. C., and Mitcheson, J. S. (2005) Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 26, 119-124.
64. Cavalli, A., Poluzzi, E., De Ponti, F., and Recanatini, M. (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. 45, 3844-3853.
65. Ekins, S., Crumb, W. J., Sarazan, R. D., Wikel, J. H., and Wrighton, S. A. (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 301, 427-434.